Stonepine Capital Management, LLC Buys Ligand Pharmaceuticals Inc, Stemline Therapeutics Inc, Cidara Therapeutics Inc, Sells Oxford Immunotec Global PLC, Adamas Pharmaceuticals Inc, Affimed NV

• New Purchases: LGND, STML, CDTX, BDSI, F2KA, SPNE, AGTC, BXRX, ATRS, RIGL,
• Added Positions: CBIO, CTIC, CHMA, EOLS, OPNT, PF42, XOMA, APEN, CPIX,
• Reduced Positions: AMRN, OXFD, ADMS, ISEE, AFMD, HTGM, NEOS,
• Sold Out: NVLNF, APVO, SBBP, SCYX, TORC, ACER,

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/stonepine+capital+management%2C+llc/current-portfolio/portfolio

1. Ligand Pharmaceuticals Inc (LGND) - 160,919 shares, 12.77% of the total portfolio. New Position
2. IVERIC bio Inc (ISEE) - 2,583,786 shares, 9.70% of the total portfolio. Shares reduced by 13.87%
3. CTI BioPharma Corp (CTIC) - 6,430,637 shares, 6.45% of the total portfolio. Shares added by 71.26%
4. Amarin Corp PLC (AMRN) - 1,313,100 shares, 5.73% of the total portfolio. Shares reduced by 15.35%
5. Affimed NV (AFMD) - 3,000,000 shares, 5.17% of the total portfolio. Shares reduced by 25.19%

Stonepine Capital Management, LLC initiated holding in Ligand Pharmaceuticals Inc. The purchase prices were between $63.37 and $107.88, with an estimated average price of $91.15. The stock is now traded at around $94.10. The impact to a portfolio due to this purchase was 12.77%. The holding were 160,919 shares as of .

Stonepine Capital Management, LLC initiated holding in Stemline Therapeutics Inc. The purchase prices were between $3.41 and $10.79, with an estimated average price of $6.56. The stock is now traded at around $12.15. The impact to a portfolio due to this purchase was 4.68%. The holding were 886,632 shares as of .

Stonepine Capital Management, LLC initiated holding in Cidara Therapeutics Inc. The purchase prices were between $1.74 and $4.26, with an estimated average price of $3.02. The stock is now traded at around $2.92. The impact to a portfolio due to this purchase was 3.52%. The holding were 1,302,981 shares as of .

Stonepine Capital Management, LLC initiated holding in BioDelivery Sciences International Inc. The purchase prices were between $3.06 and $6.32, with an estimated average price of $4.96. The stock is now traded at around $4.39. The impact to a portfolio due to this purchase was 3.12%. The holding were 755,000 shares as of .

Stonepine Capital Management, LLC initiated holding in DiaMedica Therapeutics Inc. The purchase prices were between $1.84 and $5.15, with an estimated average price of $3.71. The stock is now traded at around $3.70. The impact to a portfolio due to this purchase was 2.52%. The holding were 825,297 shares as of .

Stonepine Capital Management, LLC initiated holding in SeaSpine Holdings Corp. The purchase prices were between $6.08 and $16.42, with an estimated average price of $13.23. The stock is now traded at around $9.80. The impact to a portfolio due to this purchase was 2.26%. The holding were 253,131 shares as of .

Stonepine Capital Management, LLC added to a holding in Catalyst Biosciences Inc by 231.68%. The purchase prices were between $3.5 and $8.51, with an estimated average price of $6.16. The stock is now traded at around $6.19. The impact to a portfolio due to this purchase was 3.39%. The holding were 1,019,196 shares as of .

Stonepine Capital Management, LLC added to a holding in CTI BioPharma Corp by 71.26%. The purchase prices were between $0.69 and $1.58, with an estimated average price of $1.16. The stock is now traded at around $1.06. The impact to a portfolio due to this purchase was 2.68%. The holding were 6,430,637 shares as of .

Stonepine Capital Management, LLC added to a holding in Chiasma Inc by 305.17%. The purchase prices were between $2.98 and $5.18, with an estimated average price of $4.45. The stock is now traded at around $5.23. The impact to a portfolio due to this purchase was 2.23%. The holding were 744,134 shares as of .

Stonepine Capital Management, LLC added to a holding in Evolus Inc by 108.40%. The purchase prices were between $3.53 and $12.21, with an estimated average price of $8.59. The stock is now traded at around $3.63. The impact to a portfolio due to this purchase was 1.94%. The holding were 822,960 shares as of .

Stonepine Capital Management, LLC added to a holding in Interpace Biosciences Inc by 88.90%. The purchase prices were between $0.58 and $9.8, with an estimated average price of $6.33. The stock is now traded at around $5.05. The impact to a portfolio due to this purchase was 0.48%. The holding were 178,295 shares as of .

Stonepine Capital Management, LLC sold out a holding in Novelion Therapeutics Inc. The sale prices were between $0.7 and $0.8, with an estimated average price of $0.73.

Stonepine Capital Management, LLC sold out a holding in Aptevo Therapeutics Inc. The sale prices were between $3.29 and $9.73, with an estimated average price of $6.81.

Stonepine Capital Management, LLC sold out a holding in Strongbridge Biopharma PLC. The sale prices were between $1.57 and $3.51, with an estimated average price of $2.6.

Stonepine Capital Management, LLC sold out a holding in SCYNEXIS Inc. The sale prices were between $0.55 and $1.15, with an estimated average price of $0.9.

Stonepine Capital Management, LLC sold out a holding in resTORbio Inc. The sale prices were between $0.87 and $1.7, with an estimated average price of $1.33.

Stonepine Capital Management, LLC sold out a holding in Acer Therapeutics Inc. The sale prices were between $1.18 and $5.86, with an estimated average price of $3.7.